
UK - Imperial Innovations leads £2m Cell Medica funding
Imperial Innovations Group has led a funding round worth close to £2m for cellular therapeutics company Cell Medica, alongside private investors.
Imperial Innovations invested £1.16m to the round and appointed investment manager Maina Bhaman to the company's board.
Launched in 2007 with funding from Imperial Innovations and the Wellcome Trust, Cell Medica is commericalising clinically proven cell therapy techniques, some of which are developed at Imperial College London. The company's lead clinical application involves the transfer of donor-derived virus-specifc T cells into a patient in order to prevent infections following bone marrow transplant.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater